Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 5
1985 2
1986 23
1987 29
1988 21
1989 33
1990 41
1991 53
1992 35
1993 31
1994 40
1995 45
1996 47
1997 32
1998 40
1999 43
2000 39
2001 35
2002 32
2003 42
2004 50
2005 45
2006 56
2007 55
2008 50
2009 40
2010 35
2011 43
2012 50
2013 52
2014 29
2015 42
2016 34
2017 42
2018 25
2019 22
2020 27
2021 23
2022 17
2023 23
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

1,366 results

Results by year

Filters applied: . Clear all
Page 1
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, Variava E, Black J, Oluboyo P, Gwentshu N, Ngam E, Ackerman T, Marais L, Mottay L, Meier S, Pooran A, Tomasicchio M, Te Riele J, Derendinger B, Ndjeka N, Maartens G, Warren R, Martinson N, Dheda K. Esmail A, et al. Am J Respir Crit Care Med. 2022 May 15;205(10):1214-1227. doi: 10.1164/rccm.202107-1779OC. Am J Respir Crit Care Med. 2022. PMID: 35175905 Clinical Trial.
Methods: Participants were randomly assigned (1:1 ratio) to a 6-month all-oral regimen that included levofloxacin, bedaquiline, and linezolid, or the standard-of-care (SOC) 9-month World Health Organization (WHO)-approved injectable-based regimen. ...Conclusions: Compared …
Methods: Participants were randomly assigned (1:1 ratio) to a 6-month all-oral regimen that included levofloxacin, bedaquiline, and l …
Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial.
Paradkar MS, Devaleenal D B, Mvalo T, Arenivas A, Thakur KT, Wolf L, Nimkar S, Inamdar S, Giridharan P, Selladurai E, Kinikar A, Valvi C, Khwaja S, Gadama D, Balaji S, Yadav Kattagoni K, Venkatesan M, Savic R, Swaminathan S, Gupta A, Gupte N, Mave V, Dooley KE; TuBerculous Meningitis in Kids (TBM-KIDS) Study Team. Paradkar MS, et al. Clin Infect Dis. 2022 Oct 29;75(9):1594-1601. doi: 10.1093/cid/ciac208. Clin Infect Dis. 2022. PMID: 35291004 Free PMC article. Clinical Trial.
Participants received isoniazid and pyrazinamide plus: (i) high-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, arm 1); (ii) high-dose rifampicin and levofloxacin (R30HZL, arm 2); or (iii) standard-dose rifampicin and ethambutol (R15HZE, arm 3) for 8 weeks, followed by …
Participants received isoniazid and pyrazinamide plus: (i) high-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, arm 1); (ii) high-dose ri …
Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial.
Messous S, Trabelsi I, Bel Haj Ali K, Abdelghani A, Ben Daya Y, Razgallah R, Grissa MH, Beltaief K, Mezgar Z, Belguith A, Bouida W, Boukef R, Boubaker H, Msolli MA, Sekma A, Nouira S. Messous S, et al. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099729. doi: 10.1177/17534666221099729. Ther Adv Respir Dis. 2022. PMID: 35657073 Free PMC article. Clinical Trial.
Typical administration periods range from 5 to 7 days. A 2-day course with levofloxacin was not previously assessed. We performed a randomized clinical trial to evaluate the efficacy of 2-day versus 7-day treatment with levofloxacin in patients with AECOPD. METHODS …
Typical administration periods range from 5 to 7 days. A 2-day course with levofloxacin was not previously assessed. We performed a r …
Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.
Sippola S, Haijanen J, Grönroos J, Rautio T, Nordström P, Rantanen T, Pinta T, Ilves I, Mattila A, Rintala J, Löyttyniemi E, Hurme S, Tammilehto V, Marttila H, Meriläinen S, Laukkarinen J, Sävelä EL, Savolainen H, Sippola T, Aarnio M, Paajanen H, Salminen P. Sippola S, et al. JAMA. 2021 Jan 26;325(4):353-362. doi: 10.1001/jama.2020.23525. JAMA. 2021. PMID: 33427870 Free PMC article. Clinical Trial.
Patients randomized to receive intravenous antibiotics followed by oral antibiotics (n = 288) received intravenous ertapenem (1 g/d) for 2 days followed by oral levofloxacin (500 mg/d) and metronidazole (500 mg 3 times/d) for 5 days. ...CONCLUSION AND RELEVANCE: Among adul …
Patients randomized to receive intravenous antibiotics followed by oral antibiotics (n = 288) received intravenous ertapenem (1 g/d) for 2 d …
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN, Yim JJ; MDR-END investigators. Mok J, et al. Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9. Lancet. 2022. PMID: 36522208 Clinical Trial.
The investigational group received delamanid, linezolid, levofloxacin, and pyrazinamide for 9 months, and the control group received a conventional 20-24-month regimen, according to the 2014 WHO guidelines. ...INTERPRETATION: 9-month treatment with oral delamanid, linezoli …
The investigational group received delamanid, linezolid, levofloxacin, and pyrazinamide for 9 months, and the control group received …
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ, Chen PY, Fang YJ, Bair MJ, Chen CC, Chen CC, Yang TH, Lee JY, Yu CC, Kuo CC, Chiu MC, Chou CK, Chen CY, Hu WH, Tsai MH, Hsu YC, Shun CT, Luo JC, Lin JT, El-Omar EM, Wu MS, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Chen MJ, et al. Lancet Gastroenterol Hepatol. 2023 Jul;8(7):623-634. doi: 10.1016/S2468-1253(23)00097-3. Epub 2023 May 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37178702 Clinical Trial.
In H pylori strains, point mutations in the 23S rRNA and gyrA genes are associated with clarithromycin resistance and levofloxacin resistance, respectively. Whether the efficacy of molecular testing-guided therapy is non-inferior to that of susceptibility testing-guided th …
In H pylori strains, point mutations in the 23S rRNA and gyrA genes are associated with clarithromycin resistance and levofloxacin re …
Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection.
Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Yu J, et al. World J Gastroenterol. 2023 May 28;29(20):3133-3144. doi: 10.3748/wjg.v29.i20.3133. World J Gastroenterol. 2023. PMID: 37346155 Free PMC article. Clinical Trial.
The eradication rate did not differ with the number of treatment failures (P = 0.433). The rates of clarithromycin, metronidazole, and levofloxacin resistance were 91.3% (21/23), 100.0% (23/23), and 60.9% (14/23), respectively. ...In 60.9% (14/23) patients, the H. pylori i …
The eradication rate did not differ with the number of treatment failures (P = 0.433). The rates of clarithromycin, metronidazole, and le
Efficacy And Cost-Effectiveness, Comparison Of 7-Days Vonoprazan Versus 14-Days Esomeprazole Based Triple Therapies For Treating Helicobacter Pylori Infection In Pakistani Population: A Randomized Clinical Trial.
Waqar F, Noor M, Farhat K, Ali S, Haider E, Fatima Gillani SF. Waqar F, et al. J Ayub Med Coll Abbottabad. 2023 Oct-Dec;35(Suppl 1)(4):S746-S751. doi: 10.55519/JAMC-S4-12110. J Ayub Med Coll Abbottabad. 2023. PMID: 38406904 Free article. Clinical Trial.
The Esomeprazole group received 14 days of triple therapy orally with Esomeprazole 20 mg twice a day; Amoxicillin 1000 mg twice a day; and Levofloxacin 500 mg one time a day. The comparative Vonoprazan group was given 7-days triple therapy orally with Vonoprazan 20 mg twic …
The Esomeprazole group received 14 days of triple therapy orally with Esomeprazole 20 mg twice a day; Amoxicillin 1000 mg twice a day; and …
A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection.
Li Y, Yin Y, Peng X, Zheng H, Fu F, Liu Z, Wu X, Wu X, Zheng S, Chen N, He L, Ren L, Ni Z, Li D, Liang P, Lv X, Zhang Y. Li Y, et al. Ann Med. 2021 Dec;53(1):217-226. doi: 10.1080/07853890.2020.1861322. Ann Med. 2021. PMID: 33331182 Free PMC article. Clinical Trial.
METHODS: In this randomized, active-controlled clinical trial, the patients with acute uncomplicated UTI were randomized to receive sitafloxacin 100-mg once-daily (qd) or levofloxacin 500-mg qd orally for 3-5 days. The patients with complicated UTI were randomized to recei …
METHODS: In this randomized, active-controlled clinical trial, the patients with acute uncomplicated UTI were randomized to receive sitaflox …
Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study.
Takahashi M, Iwasaki S, Kawano T, Ikoma R, Oka S, Terasaki M, Sato H, Kariya S, Takahashi H. Takahashi M, et al. Auris Nasus Larynx. 2023 Aug;50(4):521-533. doi: 10.1016/j.anl.2022.12.013. Epub 2023 Jan 3. Auris Nasus Larynx. 2023. PMID: 36599786 Free article. Clinical Trial.
OBJECTIVE: The present study aimed to evaluate the efficacy and safety of 1.5% levofloxacin (LVFX) otic solution for the treatment of patients with otitis media. ...
OBJECTIVE: The present study aimed to evaluate the efficacy and safety of 1.5% levofloxacin (LVFX) otic solution for the treatment of …
1,366 results